197: Photochemically-Treated (PCT) Sensitized Cytotoxic T Cells and Anti-NK1.1 Antibody Pre-Treatment Promote Both T and B Cell Reconstitution in Non-Leaky Artemis Deficient Mice with Severe Combined Immunodeficiency Disease (SCID)  by Xiao, Z. et al.
Immune reconstitution in Artemis-deficient mice following allogeneic
mismatched HSCT
4 Wks Post HSCT 8 Wks Post HSCT
Marrow Prep
and Pre
Treatment (n) T Cells1 B Cells T Cells B Cells
HSC (5)2 0 0 N/A N/A
HSC/Anti-NK1.1(5) 0.20 ± 0.1 0.12 ± 0.1 0.51 ± 0.2 0.39 ± 0.2
HSC/PCT
sensitized
T cells (3)
0 0 N/A N/A
HSC/PCT
sensitized
T cells/Anti-NK1.1
(n 5 10 at 4 wks
and n 5 4 at 8 wks)
19.4 ± 11.8 22.4 ± 15.8 57.5 ± 26.7 30.7 ± 26.2
1Percent of CD31 T cells or CD45R/B2201 B cells in CD451
lymphocyte gate.
2
Poster Session I 7347%, CR3 or greater 18%, and not in remission in 11%. The me-
dian TNC infused was 4.06  10 7/kg (range, 0.73–28  10 7/kg),
median CD34 cells infused 2.3  10 5/kg (range, 0.3–31.7  10 5/
kg). HLA matching was 6/6 (23), 5/6 (31), and 4/6 (14). Condition-
ing was TBI-based in 66% and non-TBI in 34%. GVHD prophy-
laxis was cyclosporine and steroids in 91%, cyclosporine and
Methotrexate1/- steroids in 7%, and other in 2%. Median engraft-
ment times were 23.5 days for neutrophils and 65 days for platelets.
Acute GVHD had a median day of onset of 25 days (range, 10–93
days), with grade II-IV seen in 49% and grade III-IV in 25% of pa-
tients. The pattern of organ involvement with GVHD is shown in
the TableTable below. Isolated GI involvement was seen in 23%
of patients with grade III-IV acute GVHD. Event free survival at
1 and 2 yr were 62% and 58% for patients without acute GVHD,
75% and 56% for grade II only, and 53% and 47% for grade III-
IV acute GVHD. Survival with higher grade GVHD may be related
to both the more delayed onset of GVHD and more manageable
course of GVHD after UCBT.
Pattern of organs involved by acute GVHD
Organ system involved (%) HSC 5 lin- c-kit1 cells; 100,000 cells injected/animal.Acute GVHD
maximum gradeNo. of
patients Liver GI SkinGrade I 3 0 0 100%
Grade II 16 6% 50% 87%
Grade III 12 16% 100% 66%
Grade IV 5 80% 100% 100%
Total 36Table 1. HSCT details and outcome
Patient
Sex/Age (y)/
Diagnosis Graft
Nucleated
cell dose
108/Kg
Follow
up (mo)
ANC
500/platelets
50K/%donor GVHD Events/Lansky
1 F/12/thalassemia 8/8 BM MSD 2.2 53 17/103/97 No -/100
2 M/2/thalassemia 8/8 BM MSD 3.4 23 18/25/100 No -/100
3 M/0.8/thalassemia 8/8 BM MSD 5.8 8 11/22/61 No -/100
4 M/2.5/Sickle cell D 8/8 BM MSD 3.3 48 13/20/100 No -/100
5 F/9/Sickle cell D 5/6 UCB URD 0.42 22 (died) 16/-/100 chronic
extensive
GVHD, infection
6 M/15/Sickle cell D 8/8 BM MSD 2.31 13 12/65/100 chronic
limited
DLI for 53% donor
chimerism/100
7 F/17/SCD 6/8 BM URD 3.22 10 11/22/100 No Pneumatosis,
sz (resolved)/90
8 M/11/Sickle cell D 8/8 BM URD 6 9 16/19/97 grade 2
acute
hemolysis,
CMV/100
9 M/16/Sickle cell D 6/8 PB URD
T depleted
1.1 CD34 6 12/did
not drop/0
- graft rejection/
autologous
recovery
10 M/18/Sickle cell D 8/8 BM URD 4 1.5 13/14/97 grade 4 gut
(resolved)
GVHD/90197
PHOTOCHEMICALLY-TREATED (PCT) SENSITIZED CYTOTOXIC T CELLS
AND ANTI-NK1.1 ANTIBODY PRE-TREATMENT PROMOTE BOTH T
AND B CELL RECONSTITUTION IN NON-LEAKY ARTEMIS DEFICIENT
MICE WITH SEVERE COMBINED IMMUNODEFICIENCY DISEASE (SCID)
Xiao, Z., Dunn, E., Singh, K., Ibeid, R., Cowan, M.J. UCSF Children’s
Hospital, San Francisco, CA.
Artemis-deficiency results in T-B-NK1 SCID. It has a high in-
cidence in Athabascan-speaking Native Americans (SCIDA), and
is associated with increased sensitivity to alkylating agents and ion-
izing radiation. We previously reported a murine model of Artemis-
deficiency (mArt-/-) that unlike children with SCIDA, had a leaky
phenotype with some T cell numbers and function. We backcrossed
this mutation onto C57BL/6 (B6) mice and compared the pheno-
type to mArt-/- 129/SvJ ‘‘leaky’’ mice. We found that the %129/
SvJ in the background significantly correlated with increasing leak-
iness. B6 mArt-/- mice have virtually no leakiness based on pheno-
typing and function, comparable to SCIDA children. When
injected into 8 w/o mArt-/- recipients, we found that 1  105
Balb/c allomismatched lineage depleted and c-kit enriched (lin- c-
kit1) hematopoietic stem cells (HSC) were rejected (Table). Anti-
NK1.1 antibody pre-treatment resulted in limited engraftment.
We wanted to develop a non-chemotherapy based approach to pro-
moting engraftment. We generated Balb/c donor T cells sensitized
to B6 mice and treated them with Uvadex and UVA photochemical
therapy (PCT) which inhibits proliferation but not cytotoxic func-
tion. When 6  105 PCT sensitized Balb/c CD31 T cells were co-
injected with 1  105 Balb/c HSC into NK-reduced mArt-/- 8 wk
old mice, significant T and B cell reconstitution occurred by 4
wks post transplant with no evidence of GvHD at 8 wks (Table).
However, no engraftment appeared without anti-NK1.1 antibody
pre-treatment. These results indicate that both PCT sensitized
CD31 T cells and anti-NK1.1 antibody pre-treatment are neces-
sary to enhance the immune reconstitution following an allogeneic
HSCT. This non leaky Artemis-deficient mouse model more
closely resembles the phenotype seen in children with Artemis de-
ficiency including resistance to mismatched allogeneic cells and is
ideal for studying novel ways of correcting the immune deficiency
in SCID patients without using conditioning therapy with alkylat-
ing agents or ionizing radiation.198
ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHILDRENWITH HE-
MOGLOBINOPATHY USING REDUCED INTENSITY CONDITIONING
Shenoy, S.1, DeBaun, M.1, Kamani, N.2, Adams, R.3, Grimley, M.4,
Wall, D.4, Gilman, A.5, Barnes, Y.1, Witty, S.1, Yu, L.6. 1 Washington
University School of Medicine, St. Louis, MO; 2 Children’s National
Medical Center, Washington DC; 3 Mayo Clinic, Phoenix, AZ; 4 Texas
Transplant Institute, San Antonio, TX; 5 UNC Lineberger Comprehen-
sive Cancer Center, Chapel Hill, NC; 6 Louisiana State University,
New Orleans, LA.
Background and Objective: Allogeneic hematopoietic stem cell
transplantation (HSCT) can establish normal red cell hematopoie-
sis and control hemoglobinopathy associated organ damage suc-
cessfully in children. However, HSCT is limited by donor
availability, conditioning related toxicities, and graft versus host dis-
ease (GVHD). Graft rejection rates are high especially after non-
myeloablative conditioning. HSCT is largely restricted to matched
sibling donor (MSD) transplants following myeloablative condi-
tioning. A multi-center trial using reduced intensity conditioning
(RIC) was developed for non-malignant disorders to decrease
